Formulation and evaluation of amlodipine immediate release tablets
DOI:
https://doi.org/10.47957/ijpda.v13i4.670Keywords:
Amlodipine, Calcium channel blocker, Hypertension, Vasodilation, Once-daily dosing, Cardiovascular risk reductionAbstract
Amlodipine is a long-acting dihydropyridine calcium channel blocker widely used in the management of hypertension and angina pectoris. Its primary mechanism of action involves inhibition of calcium ion influx into vascular smooth muscle, leading to peripheral arterial vasodilation and reduced systemic vascular resistance. Due to its slow onset and prolonged duration of action, amlodipine provides effective 24-hour blood pressure control with once-daily dosing. It has a favorable safety profile, with common adverse effects including peripheral edema, dizziness, and flushing. Amlodipine has also been shown to reduce cardiovascular morbidity when used as part of antihypertensive therapy, either alone or in combination with other agents. Ongoing research continues to explore its role in vascular protection, metabolic neutrality, and combination therapy strategies for optimized cardiovascular risk reduction.
Downloads
References
Charman SA, Charman WN. Oral modified-release delivery systems. In: Rathbone MJ, Hadgraft J, Roberts MS, editors. Modified-release drug delivery technology. New York: Marcel Dekker; 2003. p. 1–10.
Mehta RM. Pharmaceutics I. 3rd ed. New Delhi: Vallabh Prakashan; 2002. p. 7, 238.
Ghosh T, Ghosh A, Prasad D. A review on new generation orodispersible tablets and its future prospective. Int J Pharm Pharm Sci. 2011;3(1):1–7.
Gabrielsson J, Lindberg NO, Lundstedt T. Multivariate methods in pharmaceutical applications. J Chemom. 2002;16:141–160.
Kilor V, Sapkal N, Awari J, Shewale B. Development and characterization of enteric-coated immediate-release pellets of aceclofenac by extrusion/spheronization technique using carrageenan as a pelletizing agent. AAPS PharmSciTech. 2010;11(1):336–343.
Govedarica B, Radelnjac J, Dreu R, Sr?i? S. Formulation and evaluation of immediate release tablets with different types of paracetamol powders prepared by direct compression. Afr J Pharm Pharmacol. 2011;5(1):31–41.
National Institute for Health and Care Excellence (NICE). Hypertension: management in adults in primary care (CG034). London: NICE; 2006. p. 19.
Wang JG, et al. Amlodipine in the current management of hypertension. J Clin Hypertens. 2023;25(1):3–14.
Fares H. Amlodipine in hypertension: a first-line agent with efficacy and safety. Open Heart. 2016;3(2):e000473.
Gao Y, et al. Effect of amlodipine on ventricular hypertrophy in patients with hypertension: a meta-analysis. Ann Transl Med. 2021;9(8):1–10.
Sheraz MA. Formulations of amlodipine: a review. J Pharm Bioallied Sci. 2016;8(1):1–9.
de Portu S, et al. Amlodipine: a pharmacoeconomic review. J Med Econ. 2009;12(2):1–10.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The CAMELOT study. JAMA. 2003;289(24):3170–3178. doi:10.1001/jama.289.24.3170.
Iyengar SS, Mohan JC, Ray S, et al. Effect of amlodipine in stroke and myocardial infarction: a systematic review and meta-analysis. Cardiol Ther. 2021;10:429–444. doi:10.1007/s40119-021-00239-1.
Lee SA, Choi HM, Park HJ, Ko SK, Lee HY. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. Korean J Intern Med. 2014;29(3):315–324. doi:10.3904/kjim.2014.29.3.315.
Iyengar SS, Mohan JC, Ray S, et al. Effect of amlodipine in stroke and myocardial infarction: a systematic review and meta-analysis. Cardiol Ther. 2021;10(3):429–444.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
